Delayed Generic Entry
Counsel for a branded pharmaceutical company retained Dr. Michael Keeley, a senior vice president of Cornerstone Research, to address class certification issues in two antitrust suits brought by classes of…
Direct Purchaser Antitrust Suit
Counsel for a leading U.S. manufacturer of medical devices retained Dr. Michael Keeley, a senior vice president of Cornerstone Research, to address class certification issues in an antitrust case brought…
Exclusionary Practices in Managed Care Organizations’ Contracts
Cornerstone Research worked with the defense experts in a series of antitrust cases against the manufacturer of a branded drug with a dominant market share in its therapeutic class.
Express Scripts, Inc., PBM Litigation
In a proposed class action against pharmacy benefit manager (PBM) Express Scripts, Inc., the named plaintiffs sought to represent five proposed classes of self-funded ERISA plans.
Failure to Disclose Clinical Trial Results
Counsel for a pharmaceutical company retained Cornerstone Research to assess damages in a securities class action alleging the company misled investors about a drug’s approval probability.
High-Technology Medical Devices
A leading manufacturer of high-technology medical devices retained Dr. Matthew Lynde, a vice president of Cornerstone Research, to evaluate the patent infringement damages claims of the plaintiff, another manufacturer of…
Hilton v. Children’s Hospital San Diego
Counsel for the defendants retained Dr. Michael Keeley, a senior vice president of Cornerstone Research, to evaluate the plaintiff’s antitrust claims from an economic perspective and to assess the validity…
Irreparable Harm
Cornerstone Research has worked with Professor Henry Grabowski of Duke University on a number of cases to evaluate whether the incumbent branded drug company would suffer irreparable harm if the…
Misleading Disclosure of Clinical Trial Results
Plaintiffs filed a securities class action against a major pharmaceutical company alleging that the company made false and misleading statements regarding the results of a drug’s safety study.
Pharmaceutical Product Misrepresentation Class Action
In a class action against a large pharmaceutical company, the plaintiffs alleged that the pharmaceutical company provided false and misleading information about the efficacy and safety of its products, resulting…
How can we help you?
If you are looking for a publication not on our website, contact us.